Didam

Researchers are evaluating the safety and effectiveness of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device combined with pembrolizumab and platinum-based chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) that has spread to other parts of the body. This Phase 3 randomized study aims to compare overall survival and progression-free survival between patients receiving this combination treatment and those receiving pembrolizumab with platinum-based chemotherapy alone. Additional analysis will examine outcomes based on lung cancer subtype and PD-L1 expression levels. The NovoTTF-200T is a portable, battery-operated device designed for continuous home use that emits electric fields to disrupt cancer cell division. Participants will receive this device alongside pembrolizumab, an immune checkpoint inhibitor, and standard platinum-based chemotherapy. The study will stratify patients by cancer histology, PD-L1 expression, and previous immunotherapy treatment. Treatments will be given according to the study protocol at approximately 130 sites globally. Participants will be monitored for up to six years to assess overall survival and progression-free survival using standardized criteria. The study includes regular evaluations of tumor response, safety, and other clinical outcomes. Participants must have good performance status and adequate organ function to join. The research team will collect data on cancer progression and survival to better understand the potential benefits and risks of adding TTFields to standard therapies for metastatic NSCLC.